You are here

Article Text

Article menu
Download PDFPDF
Letter
Intravitreal triamcinolone acetonide and central serous chorioretinopathy
  1. J B Jonas,
  2. B A Kamppeter
  1. Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, Ruprecht-Karls-University of Heidelberg, Germany
  1. Correspondence to: J Jonas Universitäts-Augenklinik, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany; Jost.Jonasaugen.ma.uni-heidelberg.de

https://doi.org/10.1136/bjo.2004.054247

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Intravitreal injections of triamcinolone acetonide have increasingly been performed as treatment for intraocular diseases with intraretinal oedema and with subfoveal fluid accumulation, such as diffuse diabetic macular oedema, persistent pseudophakic cystoid macular oedema, central retinal vein occlusion, and exudative age related macular degeneration.1–4 In view of the widening spectrum of indications for intravitreal triamcinolone acetonide injections, it was the purpose of this study to evaluate whether intravitreal triamcinolone acetonide injections may be useful as treatment of longstanding central serous chorioretinopathy.

    CASE REPORT

    A 50 year old patient presented with a decrease in visual acuity to 1/20 in his right eye because of …

    View Full Text

    Footnotes

    • Proprietary interest: None.